EUCTR2008-006444-19-SE进行中（未招募）不适用
AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 328
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All of the following inclusion criteria need to be fulfilled:
- •· Diagnosis of acute ischemic stroke with an onset within 9 hours prior to
- •start of study agent administration.
- •· ischemic stroke in the MCA territory confirmed by MRI (diffusion)
- •· men and women aged = 18 years and = 85 years
- •· NIHSS score = 6 and =22
- •· lesion size on DWI: on the slice showing the largest extension of the
- •infarct the largest diameter of the lesion should have at least 3 cm and
- •should show on at least 3 consecutive slices; if the rule cannot be
- •applied (e.g. due to an irregular shape or partially separate volumes on
- •the slice), but in the clinical judgment the lesion is = 15 cm3, the patient
- •should be included in the clinical study if the investigator can provide a
- •written justification
- •· written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting any of the following criteria will be excluded from randomization:
- •· Participation in another study with an investigational drug or device within
- •the last 30 days or planned participation in another trial
- •· Prior to current stroke: Inability to walk or to lead an independent life; prestroke
- •BI score < 95 or pre-stroke mRS score > 1
- •· Life expectancy considered to be less or equal 6 months in the judgment
- •of the investigator
- •· Neurological deficit that has led to stupor or coma (suspicious of
- •malignant hemispheric stroke)
- •· Infarct is lacunar
- •· Any evidence of ICH by imaging.Patients with cerebral micro-bleedings can be included in the study.
- •· Current malignant hypertension with systolic and diastolic blood pressure
- •> 220 mmHg and > 120 mmHg, respectively
- •· Strong clinical suspicion of septic embolus
- •· Any thrombosis involving the cerebral veins
- •· High clinical suspicion of vasculitis (e.g. multiple caliber irregularities of
- •intracerebral vessels on MRA plus history of vasculitis)
- •· Any MRI finding indicating that there might be a non-vascular cause for
- •the present neurological symptoms
- •· Any signs on imaging of a mass effect causing shift of midline structures
- •· Presence or history of active malignancies within one year preceding
- •randomization, especially
- •hematological malignancies or
- •myeloproliferative diseases
- •· A platelet count < 100 /nl at V0
- •· A leukocyte count >20 /nl at V0
- •· Congenital neutropenia
- •· Other serious illness, e.g., severe hepatic, cardiac, or renal failure, acute
- •myocardial infarction or a complex disease that may confound treatment
- •· Any suspected hypersensitivity and/or contraindication to any ingredients
- •of the study medication
- •· Patients currently receiving G-CSF or GM-CSF
- •· Thrombolytic drug treatment outside the recommendations of the current ESO Guidelines for Management of Ischemic Stroke and Transient Ischemic Attack 200, especially if the treatment was initiated > 4.5 hrs after stroke onset, or the patient had recent severe or dangerous bleeding prior treatment, or despite anticoagulant or heparin treatment.
- •· Patients for which any of the following treatments are planned for acute recanalisation of intracranial vessels:use of mechanical devices for clot retraction like the Merci Retriever of the Penumbra System, or any vessel dilation or stenting procedure.
- •· Pregnant or lactating women (for women of childbearing potential a
- •negative serum pregnancy test is required at V0). Women of childbearing potential that have not used an acceptable method of contraception (e.g. hormonal implants, injectables, combined oral contraceptives, intrauterine devices (IUDs) within one month prior to entry into the study.
- •· Patients with a history of active substance abuse (including alcohol) for
- •the last 2 years
研究者
相似试验
进行中（未招募）
不适用
AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trialischemic strokeMedDRA version: 9.1Level: LLTClassification code 10061256Term: Ischaemic strokeEUCTR2008-006444-19-ATSYGNIS Bioscience GmbH & Co. KG328
进行中（未招募）
不适用
AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trialischemic strokeMedDRA version: 9.1Level: LLTClassification code 10061256Term: Ischaemic strokeEUCTR2008-006444-19-CZSYGNIS Bioscience GmbH & Co. KG328
进行中（未招募）
不适用
AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trialischemic strokeMedDRA version: 14.0Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-006444-19-DESYGNIS Bioscience GmbH & Co. KG328
进行中（未招募）
1 期
AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trialischemic strokeMedDRA version: 9.1Level: LLTClassification code 10061256Term: Ischaemic strokeEUCTR2008-006444-19-ESSYGNIS Bioscience GmbH & Co. KG350
进行中（未招募）
1 期
AXIS 2: AX200 for the treatment of ischemic strokeA multinational, multicenter, randomized, doubleblind,placebo-controlled, phase II trialEUCTR2008-006444-19-SKSYGNIS Bioscience GmbH & Co. KG328